Compare CX & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CX | ZBH |
|---|---|---|
| Founded | 1906 | 1927 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 17.6B |
| IPO Year | 2000 | 2001 |
| Metric | CX | ZBH |
|---|---|---|
| Price | $10.19 | $98.41 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 21 |
| Target Price | $12.21 | ★ $101.00 |
| AVG Volume (30 Days) | ★ 5.0M | 1.4M |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | 0.74% | ★ 1.20% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | N/A | ★ $8,231,500,000.00 |
| Revenue This Year | $8.28 | $4.96 |
| Revenue Next Year | $4.34 | $3.76 |
| P/E Ratio | ★ $19.03 | $41.55 |
| Revenue Growth | N/A | ★ 7.20 |
| 52 Week Low | $8.73 | $79.12 |
| 52 Week High | $13.67 | $106.88 |
| Indicator | CX | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 48.80 |
| Support Level | $10.46 | $85.63 |
| Resistance Level | $13.30 | $102.07 |
| Average True Range (ATR) | 0.23 | 2.58 |
| MACD | 0.02 | -0.88 |
| Stochastic Oscillator | 6.05 | 43.78 |
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.